Evidence map›Paper›PMID 36880064›Full record

ArticleClinical and translational radiation oncology2023

Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial.

Amar U Kishan, Nicholas Marco, Ting Martin Ma, Michael L Steinberg, Ankush Sachdeva, Minsong Cao, Leslie K Ballas, Emily Rietdorf, Donatello Telesca, Joanne B Weidhaas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amar U KishanUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
Nicholas MarcoUniversity of California, Department of Statistics, Los Angeles, CA 90025, USA.
Ting Martin MaUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
Michael L SteinbergUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
Ankush SachdevaUniversity of California, Institute of Urologic Oncology, Los Angeles, CA 90025, USA.
Minsong CaoUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
Leslie K BallasCedars Sinai, Department of Radiation Oncology, Los Angeles, CA 90048, USA.
Emily RietdorfUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
Donatello TelescaUniversity of California, Department of Statistics, Los Angeles, CA 90025, USA.
Joanne B WeidhaasUniversity of California, Department of Radiation Oncology, Los Angeles, CA 90025, USA.
University of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionR01CA238998 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEIDHAAS, JOANNE B · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA238998
6 · The paper itself

Abstract

Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade ≥ 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.

Indexed as

Genito-urinary toxicityGermline biomarkersPROSTOXSBRT

Identifiers

PMID36880064
PMCPMC9984404
OpenAlexW4319335278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.